Related Experiment Video
Updated: Jan 9, 2026
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Intravenously administered 2'-deoxycytidine suppresses mouse myeloma tumor growth
Ayano Iwazaki1, Kimie Imai, Kunio Nakanishi
1Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan. ayano@pharm.setsunan.ac.jp
Abstract:
We examined the in vivo effects of intravenously administered 2'-deoxycytidine (dCyd) on tumor growth and survival time in mice bearing SP2/0-Ag14 (SP2/0) myeloma tumors. Administration of dCyd tended to decrease the tumor volume and significantly decreased the tumor weight. A single intravenous administration of dCyd significantly increased survival time of the tumor-bearing mice. The effect of dCyd on tumor growth was maintained for at least 1 week after the final administration. The net amount of dCyd in the kidney, liver, and spleen of the tumor-bearing mice increased 2.5 to 5.3 fold compared with the amount in non-tumor-bearing mice. Our results suggest that the increase in dCyd in the mice inoculated SP2/0 myeloma cells plays an important role for the growth suppression of the tumor.
Insights
Intravenous administration of 2'-deoxycytidine (dCyd) reduced myeloma tumor growth and increased survival time in mice. Increased dCyd levels in organs correlated with tumor suppression, suggesting a therapeutic role.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Myeloma is a cancer of plasma cells.
- SP2/0-Ag14 is a murine myeloma cell line used in research.
- 2'-deoxycytidine (dCyd) is a nucleoside with potential therapeutic applications.
Purpose of the Study:
- To investigate the in vivo effects of intravenously administered 2'-deoxycytidine (dCyd) on SP2/0 myeloma tumor growth and survival in mice.
- To determine the pharmacokinetic profile of dCyd in tumor-bearing mice.
Main Methods:
- SP2/0 myeloma tumor-bearing mice were administered dCyd intravenously.
- Tumor volume, tumor weight, and survival time were measured.
- dCyd levels in kidney, liver, and spleen were quantified.
Main Results:
- dCyd administration showed a trend towards decreased tumor volume and a significant decrease in tumor weight.
- A single intravenous dose of dCyd significantly increased survival time in tumor-bearing mice.
- dCyd levels in the kidney, liver, and spleen increased 2.5 to 5.3 fold in tumor-bearing mice compared to controls.
- The anti-tumor effect of dCyd persisted for at least one week post-administration.
Conclusions:
- Intravenous dCyd administration exhibits anti-myeloma activity in vivo.
- Increased endogenous or administered dCyd may play a role in suppressing SP2/0 myeloma tumor growth.
- dCyd demonstrates potential as a therapeutic agent for myeloma.
